2024-01-26 10:44:09 ET
DENVER, Colo., Jan. 26, 2023 ( www.247marketnews.com )- Corbus Pharmaceuticals (NASDAQ: CRBP) reported, this morning, that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Companyâ€™s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mg/kg) will be shared.
We included Corbus Pharmaceuticals in this morningâ€™s snapshot when it was trading at $19.27 up $10.83 (+128.32%), on 7.1M shares traded. Itâ€™s now at $29.225, up $20.785 (+246.27%), on 18M shares traded.
Its 52-week range is $2.11 to $33.64. Todayâ€™s high is a new 52-week high and itâ€™s trading at levels last seen in 2021.
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbusâ€™ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF? expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com .
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (â€œ24/7 MNâ€) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Few succeed in the stock market. Donâ€™t trade if youâ€™re not able to devote the necessary time. Earmark your surplus funds that youâ€™re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.
Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.
Remove emotional and psychological biases, and consider that youâ€™re competing against professionals whoâ€™re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.
For further details see:
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) and does not buy, sell, or trade any shares of (CRBP). This article does not provide a professional analysis of a (CRBP) financial position. (CRBP) financial position and all other information regarding the featured Company should be verified directly with (CRBP). Please read our full disclaimer for more detailed information.